Tag: Bigfoot Biomedical
CGM technology drives diabetes market
April 2, 2022John Andrews
As the diabetes market observes the 100th anniversary of insulin therapy, manufacturers are optimistic about the growth of medical technology in the category. Specifically, the evolution of continuous glucose meters has charted a path forward for the industry to follow, they say.
Elaine Anderson, head of the Eversense CGM business unit at Parsippany, N.J.-based Ascensia Diabetes Care, calls CGM the “first step change” in diabetes treatment since the “transformative discovery”...
Bigfoot ready for big time
January 21, 2022Theresa Flaherty, Managing Editor
MILPITAS, Calif. – Bigfoot Biomedical is gearing up to roll out its diabetes management system to a larger market after a busy 2021 that included clearance from the U.S. Food and Drug Administration.
Bigfoot launched its Unity Diabetes Management System in June to a handful of small clinics and in December it made three senior hires in business development, marketing and sales.
“We are at the point where things are taking off,” said Dr. Jim Malone, chief medical...
Bigfoot hires three, primes expansion
December 16, 2021HME News Staff
MILPITAS, Calif. – Bigfoot Biomedical, a company dedicated to better health outcomes for people with insulin-requiring diabetes, announced three senior hires with deep experience in the diabetes and health care sectors. Matthew Clemente joins Bigfoot as senior vice president of development; Robin A. Beadle joins as vice president of marketing; and Scott Snead joins as vice president of national accounts. All three positions are new to the company as it moves to expand access to its Bigfoot...
Bigfoot Biomedical receives clearance for smart insulin pen cap system
May 13, 2021HME News Staff
MILPITAS, Calif. – Bigfoot Biomedical has received 510(k) clearance from the U.S. Food and Drug Administration for its Bigfoot Unity Diabetes Management System, which features connected smart pen caps that recommend insulin doses for people using multiple daily injections. “Diabetes management is incredibly hard because insulin has no fixed dose or timing, leaving individuals to constantly determine their doses and configure devices as they make multiple critical decisions...